Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/42196
Registro completo de metadados
Campo DCValorIdioma
dc.creatorPirola, Carlos J.-
dc.creatorSookoian, Silvia-
dc.date.accessioned2020-08-04T16:40:16Z-
dc.date.available2020-08-04T16:40:16Z-
dc.date.issued2020-08-
dc.identifier.citationPIROLA, C. J.; SOOKOIAN, S. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: a meta-analysis. Journal of Infection, [S.l.], v. 81, n. 2, p. 276-281, Aug. 2020.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0163445320303297pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/42196-
dc.description.abstractBackground and rationale Some studies of hospitalized patients suggested that the risk of death and/or severe illness due to COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor type 1 blockers (ARBs). Nevertheless, some controversy still exists and there is limited information of the ACEIs/ARBs effect size on COVID-19 prognosis. Aim and Methods We aimed to measure the effect of ACEIs and/or ARBs on COVID-19 severe clinical illness by a meta-analysis. Literature search included all studies published since the COVID-19 outbreak began (December 2019) until May 9, 2020. We analyzed information from studies that included tested COVID-19 patients with arterial hypertension as comorbidity prior to hospital admission and history of taking ACEIs, ARBs, or ACEIs/ARBs. Results We included 16 studies that involved 24,676 COVID-19 patients, and we compared patients with critical (n = 4134) vs. non-critical (n = 20,542) outcomes. The overall assessment by estimating random effects shows that the use of ACEIs/ARBs is not associated with higher risk of in-hospital-death and/or severe illness among hypertensive patients with COVID-19 infection. On the contrary, effect estimate shows an overall protective effect of RAAS inhibitors/blockers (ACEIs, ARBs, and/or ACEIs/ARBs) with ∼ 23 % reduced risk of death and/or critical disease (OR: 0.768, 95%CI: 0.651-0.907, p=0.0018). The use of ACEIs (OR:0.652, 95%CI:0.478-0.891, p=0.0072) but not ACEIs/ARBs (OR:0.867, 95%CI:0.638-1.179, p =NS) or ARBs alone (OR:0.810, 95%CI:0.629-1.044, p=NS) may explain the overall protection displayed by RAAS intervention combined. Conclusion RAAS inhibitors might be associated with better COVID-19 prognosis.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceJournal of Infectionpt_BR
dc.subjectCOVID-19pt_BR
dc.subjectHypertensionpt_BR
dc.subjectDiabetespt_BR
dc.subjectCardiovascular diseasept_BR
dc.subjectPrognosispt_BR
dc.subjectRenin-Angiotensin-Aldosterone-System (RAAS) inhibitorspt_BR
dc.subjectAngiotensin II-converting enzyme inhibitorspt_BR
dc.subjectAngiotensin II receptor type 1 blockerspt_BR
dc.titleEstimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: a meta-analysispt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.